EMMVIES : Walking Training at Home in VIrtual Reality for Children With Chronic Illnesses Impacting Physical Health
NCT ID: NCT07021638
Last Updated: 2025-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2025-12-24
2027-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EMMVIES program
Evaluate the feasibility of the home training program.
EMMVIES program
Walking Training at Home in VIrtual Reality for Children with Chronic Illnesses Impacting Physical Health
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EMMVIES program
Walking Training at Home in VIrtual Reality for Children with Chronic Illnesses Impacting Physical Health
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to walk for 5 minutes on a treadmill with or without body weight support, with or without technical aids;
* Be able to understand and play virtual reality games (immersive or non-immersive);
* Be able to answer questionnaires;
* Patient affiliated to or benefiting from a social security scheme;
* Informed consent, dated and signed by parents or guardians (if minors), to participate in the study;
* Included in a care program specific to their chronic condition for at least 6 months;
* Meet the following criteria depending on the group:
PC group:
* Diagnosis of CP
* Functional level classified II or III according to the Gross Motor Function Classification System (GMFCS)
* Rehabilitation goal: improvement of gait and/or gross motor function
OB group:
* Overweight or obese, defined by a BMI above the IOTF-25 percentile
* Aim to increase daily physical activity
* No history of hip pathology
Group NM:
* Diagnosis of one of the following neuromuscular pathologies: spinal muscular atrophy type 3, Duchenne disease, congenital myopathy or Charcot Marie Tooth.
* Functional level of grade 2 to 6 on the Walton scale, or grade 3 to 7 on the Vignos scale
* Rehabilitation goal: improvement of walking and/or gross motor skills
Exclusion Criteria
* For children aged 6 to 11: in connection with the immersive virtual reality device: problems with stereoscopic vision (perception of images in 3 dimensions), unstabilized epilepsy, facial trauma \< 3 months, hearing or visual impairment, pain, dizziness or nausea caused by using immersive virtual reality.
* Patients who have undergone surgery in the last 3 months;
* Patients who have received intramuscular botulinum toxin injections in the lower limbs or intensive therapy in the 3 months prior to inclusion;
* Patient with a non-routine therapeutic program planned within 5 months that could lead to confusion with the tested program;
* Patient with insufficient understanding of the French language;
* Patient opposition (child or adolescent);
* Persons deprived of liberty by judicial or administrative decision;
* Persons under compulsory psychiatric care;
* Persons under legal protection;
6 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Angers
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Les Capucins
Angers, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mickaël DINOMAIS, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-A01261-48
Identifier Type: OTHER
Identifier Source: secondary_id
49RC24_0215
Identifier Type: -
Identifier Source: org_study_id